Products

share on google plus
Text size
view with small font size
view with medium font size
view with large font size

GRAN® / Peglasta® / Neulasta®

GRAN® (Filgrastim) is a human colony-stimulating factor (G-CSF) produced by genetic recombination technology. It works to selectively increase the count of a type of white blood cell called neurotrophil, as well as increase their functional efficacy. This enables a quick recovery from neutropenia occurring as a result of cancer chemotherapy and reduces the risk of infection, allowing for more effective chemotherapy. It also acts to relieve congenital neutropenia or neutropenia occurring after hematopoietic stem-cell transplantation (such as bone-marrow transplants). It received additional approval for application to PBSCT (peripheral blood stem cell transfusion) mobilization as well.

In Asia, Kyowa Hakko Kirin have marketed pegfilgrastim as G-LASTA® /Peglasta® /Neulasta® for chemotherapy-induced febrile neutropenia.

The Information on this website regarding Neulasta®, Filgrastim and Pegfilgrastim is not intended for audiences outside of, or to imply indications not approved in, the countries listed below. Neulasta® is a registered trademark of Amgen Inc.

Product Image

Marketed by Kyowa Hakko Kirin in

GRAN® Japan, Korea, China, Taiwan, Malaysia,
Singapore, Thailand
G-LASTA® Japan
Peglasta® Singapore, Thailand, Malaysia
Neulasta® Taiwan, Korea

To Page Top